Absence of complement component 3 does not prevent classical pathway–mediated hemolysis

Complement component 3 (C3) is emerging as a potential therapeutic target. We studied complement-mediated hemolysis using normal and C3-depleted human sera, wild-type (WT) and C3-deficient rat sera, and WT and C3 knockout rat models. In all of the in vitro and in vivo experiments, we found that the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Zhang, Lingjun, Dai, Yang, Huang, Ping, Saunders, Thomas L., Fox, David A., Xu, Jijun, Lin, Feng
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Immunobiology and Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6595256/
https://ncbi.nlm.nih.gov/pubmed/31196848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019031591
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados